Reductions in behavioral deficits and neuropathology in the R6/2 mouse model of Huntington's disease following transplantation of bone-marrow-derived mesenchymal stem cells is dependent on passage number

Stem Cell Research and Therapy

Volumn 6, Issue 1, 2015, Pages

  Rossignol, Julien ^a,b   Fink, Kyle D ^a,c,d   Crane, Andrew T ^a   Davis, Kendra K ^a   Bombard, Matthew C ^a   Clerc, Steven ^a   Bavar, Angela M ^a   Lowrance, Steven A ^a   Song, Cheng ^a   Witte, Steven ^a   Lescaudron, Laurent ^c,e   Dunbar, Gary L ^a,f  

^a Field Neurosciences Laboratory for Restorative Neurology Brain Research and Integrative Neuroscience Center HP Building   (United States)

^b Children's Hospital of Michigan   (United States)

^c UNIVERSITÉ DE NANTES   (France)

^d INSERM   (France)

^e Universite de Nantes   (France)

^f Field Neurosciences Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; MESSENGER RNA; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; HTT PROTEIN, HUMAN; HUNTINGTIN; NERVE GROWTH FACTOR; NERVE PROTEIN; TUMOR NECROSIS FACTOR;

ADULT; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CAG REPEAT; CELL CULTURE; CELL ISOLATION; CELL SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GENE; GENE EXPRESSION; HD GENE; HUNTINGTON CHOREA; IN VITRO STUDY; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; ANIMAL; ANIMAL BEHAVIOR; BONE MARROW CELL; BRAIN; CYTOLOGY; DISEASE MODEL; GENETICS; HUMAN; HUNTINGTON DISEASE; MESENCHYMAL STROMA CELL; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; TRANSGENIC MOUSE;

MUS;

ANIMALS; BEHAVIOR, ANIMAL; BONE MARROW CELLS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NERVE GROWTH FACTOR; NERVE TISSUE PROTEINS; RECEPTOR, TRKB; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84929145042     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt545     Document Type: Article

References (46)

1. Estrada Sánchez AM, Mejía-Toiber J, Massieu L: Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res 2008, 39:265-76. 10.1016/j.arcmed.2007.11.011
2. Southwell AL, Ko J, Patterson PH: Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci 2009, 29:13589-602. 10.1523/JNEUROSCI.4286-09.2009
3. Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, et al.: Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506. 10.1016/S0092-8674(00)81369-0
4. DeMarch Z, Giampà C, Patassini S, Bernardi G, Fusco FR: Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2008, 30:375-87. 10.1016/j.nbd.2008.02.010
5. Murphy KP, Carter RJ, Lione LA, Mangiarini L, Mahal A, Bates GP, et al.: Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 2000, 20:5115-23.
6. Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, et al.: Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-8. 10.1126/science.1059581
7. Zuccato C, Liber D, Ramos C, Tarditi A, Rigamonti D, Tartari M, et al.: Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol Res 2005, 52:133-9. 10.1016/j.phrs.2005.01.001
8. Dey ND, Bombard MC, Roland BP, Davidson S, Lu M, Rossignol J, et al.: Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington's disease. Behav Brain Res 2010, 214:193-200. 10.1016/j.bbr.2010.05.023
9. Jin K, LaFevre-Bernt M, Sun Y, Chen S, Gafni J, Crippen D, et al.: FGF-2 promotes neurogenesis and neuroprotection and prolongs survival in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2005, 102:18189-94. 10.1073/pnas.0506375102
10. Rossignol J, Boyer C, Lévèque X, Fink KD, Thinard R, Blanchard F, et al.: Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington's disease: morphological and behavioral outcomes. Behav Brain Res 2011, 217:369-78. 10.1016/j.bbr.2010.11.006
11. Bachoud-Lévi A-C, Gaura V, Brugières P, Lefaucheur J-P, Boissé M-F, Maison P, et al.: Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 2006, 5:303-9. 10.1016/S1474-4422(06)70381-7
12. Cicchetti F, Saporta S, Hauser RA, Parent M, Saint-Pierre M, Sanberg PR, et al.: Neural transplants in patients with Huntington's disease undergo disease-like neuronal degeneration. Proc Natl Acad Sci U S A 2009, 106:12483-8. 10.1073/pnas.0904239106
13. Keene CD, Sonnen JA, Swanson PD, Kopyov O, Leverenz JB, Bird TD, et al.: Neural transplantation in Huntington disease: long-term grafts in two patients. Neurology 2007, 68:2093-8. 10.1212/01.wnl.0000264504.14301.f5
14. Keene CD, Chang RC, Leverenz JB, Kopyov O, Perlman S, Hevner RF, et al.: A patient with Huntington's disease and long-surviving fetal neural transplants that developed mass lesions. Acta Neuropathol 2009, 117:329-38. 10.1007/s00401-008-0465-0
15. Svendsen C: Adult versus embryonic stem cells: which is the way forward? Trends Neurosci 2000, 23:450.
16. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al.: Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8:315-7. 10.1080/14653240600855905
17. Lescaudron L, Unni D, Dunbar GL: Autologous adult bone marrow stem cell transplantation in an animal model of Huntington's disease: behavioral and morphological outcomes. Int J Neurosci 2003, 113:945-56. 10.1080/00207450390207759
18. Dunbar GL, Sandstrom MI, Rossignol J, Lescaudron L: Neurotrophic enhancers as therapy for behavioral deficits in rodent models of Huntington's disease: use of gangliosides, substituted pyrimidines, and mesenchymal stem cells. Behav Cogn Neurosci Rev 2006, 5:63-79. 10.1177/1534582306289367
19. Ahmadbeigi N, Soleimani M, Gheisari Y, Vasei M, Amanpour S, Bagherizadeh I, et al.: Dormant phase and multinuclear cells: two key phenomena in early culture of murine bone marrow mesenchymal stem cells. Stem Cells Dev 2011, 20:1337-47. 10.1089/scd.2010.0266
20. Rossignol J, Boyer C, Thinard R, Remy S, Dugast A-S, Dubayle D, et al.: Mesenchymal stem cells induce a weak immune response in the rat striatum after allo or xenotransplantation. J Cell Mol Med 2009, 13:2547-58. 10.1111/j.1582-4934.2008.00657.x
21. Lescaudron L, Boyer C, Bonnamain V, Fink KD, Lévêque X, Rossignol J, et al.: Assessing the potential clinical utility of transplantations of neural and mesenchymal stem cells for treating neurodegenerative diseases. Methods Mol Biol 2012, 879:147-64. 10.1007/978-1-61779-815-3-10
22. Samadi P, Boutet A, Rymar VV, Rawal K, Maheux J, Kvann J-C, et al.: Relationship between BDNF expression in major striatal afferents, striatum morphology and motor behavior in the R6/2 mouse model of Huntington's disease. Genes Brain Behav 2013, 12:108-24. 10.1111/j.1601-183X.2012.00858.x
23. Fink KD, Rossignol J, Crane AT, Davis KK, Bombard MC, Bavar AM, et al.: Transplantation of umbilical cord-derived mesenchymal stem cells into the striata of R6/2 mice: behavioral and neuropathological analysis. Stem Cell Res Ther 2013, 4:130. 10.1186/scrt341
24. West MJ, Slomianka L, Gundersen HJ: Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991, 231:482-97. 10.1002/ar.1092310411
25. Lalonde R, Strazielle C: Brain regions and genes affecting limb-clasping responses. Brain Res Rev 2011, 67:252-9. 10.1016/j.brainresrev.2011.02.005
26. Eschenko O, Mizumori SJY: Memory influences on hippocampal and striatal neural codes: effects of a shift between task rules. Neurobiol Learn Mem 2007, 87:495-509. 10.1016/j.nlm.2006.09.008
27. Edalatmanesh M-A, Matin MM, Neshati Z, Bahrami A-R, Kheirabadi M: Systemic transplantation of mesenchymal stem cells can reduce cognitive and motor deficits in rats with unilateral lesions of the neostriatum. Neurol Res 2010, 32:166-72. 10.1179/174313209X409025
28. Im W, Ban J, Lim J, Lee M, Lee S-T, Chu K, et al.: Extracts of adipose derived stem cells slows progression in the R6/2 model of Huntington's disease. PLoS One 2013, 8:e59438. 10.1371/journal.pone.0059438
29. Morton AJ, Hunt MJ, Hodges AK, Lewis PD, Redfern AJ, Dunnett SB, et al.: A combination drug therapy improves cognition and reverses gene expression changes in a mouse model of Huntington's disease. Eur J Neurosci 2005, 21:855-70. 10.1111/j.1460-9568.2005.03895.x
30. Snyder BR, Chiu AM, Prockop DJ, Chan AWS: Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington's disease. PLoS One 2010, 5:e9347. 10.1371/journal.pone.0009347
31. Amin EM, Reza BA, Morteza BR, Maryam MM, Ali M, Zeinab N: Microanatomical evidences for potential of mesenchymal stem cells in amelioration of striatal degeneration. Neurol Res 2008, 30:1086-90. 10.1179/174313208X327955
32. Lin Y-T, Chern Y, Shen C-KJ, Wen H-L, Chang Y-C, Li H, et al.: Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in Huntington's disease mouse models. PLoS One 2011, 6:e22924. 10.1371/journal.pone.0022924
33. Bantubungi K, Blum D, Cuvelier L, Wislet-Gendebien S, Rogister B, Brouillet E, et al.: Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington's disease. Mol Cell Neurosci 2008, 37:454-70. 10.1016/j.mcn.2007.11.001
34. Sadan O, Shemesh N, Barzilay R, Bahat-Stromza M, Melamed E, Cohen Y, et al.: Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging. Stem Cells 2008, 26:2542-51. 10.1634/stemcells.2008-0240
35. Miura M, Miura Y, Padilla-Nash HM, Molinolo AA, Fu B, Patel V, et al.: Accumulated Chromosomal instability in murine bone marrow mesenchymal stem cells leads to malignant transformation. Stem Cells 2006, 24:1095-103. 10.1634/stemcells.2005-0403
36. Zhou YF, Bosch-Marce M, Okuyama H, Krishnamachary B, Kimura H, Zhang L, et al.: Spontaneous transformation of cultured mouse bone marrow-derived stromal cells. Cancer Res 2006, 66:10849-54. 10.1158/0008-5472.CAN-06-2146
37. Ciammola A, Sassone J, Cannella M, Calza S, Poletti B, Frati L, et al.: Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington's disease patients. Am J Med Genet B Neuropsychiatr Genet 2007, 144B:574-7. 10.1002/ajmg.b.30501
38. Conforti P, Ramos C, Apostol BL, Simmons DA, Nguyen HP, Riess O, et al.: Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. Mol Cell Neurosci 2008, 39:1-7. 10.1016/j.mcn.2008.04.012
39. Jiang Y, Lv H, Huang S, Tan H, Zhang Y, Li H: Bone marrow mesenchymal stem cells can improve the motor function of a Huntington's disease rat model. Neurol Res 2011, 33:331-7. 10.1179/016164110X12816242542571
40. Rehman J, Traktuev D, Li J, Merfeld-Clauss S, Temm-Grove CJ, Bovenkerk JE, et al.: Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004, 109:1292-8. 10.1161/01.CIR.0000121425.42966.F1
41. Wang M, Crisostomo PR, Herring C, Meldrum KK, Meldrum DR: Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism. Am J Physiol Regul Integr Comp Physiol 2006, 291:R880-4. 10.1152/ajpregu.00280.2006
42. McBride JL, Ramaswamy S, Gasmi M, Bartus RT, Herzog CD, Brandon EP, et al.: Viral delivery of glial cell line-derived neurotrophic factor improves behavior and protects striatal neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2006, 103:9345-50. 10.1073/pnas.0508875103
43. Bertolo A, Mehr M, Janner-Jametti T, Graumann U, Aebli N, Baur M, et al.: An in vitro expansion score for tissue-engineering applications with human bone marrow-derived mesenchymal stem cells. J Tissue Eng Regen Med 2013. http://onlinelibrary.wiley.com/doi/10.1002/term.1734/abstract
44. Chang J, Lei H, Liu Q, Qin S, Ma K, Luo S, et al.: Optimization of culture of mesenchymal stem cells: a comparison of conventional plate and microcarrier cultures. Cell Prolif 2012, 45:430-7. 10.1111/j.1365-2184.2012.00836.x
45. Lennon DP, Schluchter MD, Caplan AI: The effect of extended first passage culture on the proliferation and differentiation of human marrow-derived mesenchymal stem cells. Stem Cells Transl Med 2012, 1:279-88. 10.5966/sctm.2011-0011
46. Li X-Y, Ding J, Zheng Z-H, Li X-Y, Wu Z-B, Zhu P: Long-term culture in vitro impairs the immunosuppressive activity of mesenchymal stem cells on T cells. Mol Med Rep 2012, 6:1183-9.